A Phase II Study of Tailored-dose S-1 Plus Carboplatin Followed by Maintenance S-1 for Advanced Squamous Cell Lung Cancer: OSAKA-LCSG 1102

OBJECTIVE: A subset analysis of the LETS study suggested that S-1 plus carboplatin was more beneficial than paclitaxel plus carboplatin in terms of the overall survival (OS) in squamous cell lung cancer. However, the benefit of maintenance therapy for squamous cell non-small cell lung cancer (NSCLC)...

Descripción completa

Detalles Bibliográficos
Autores principales: Yokoi, Takashi, Minami, Seigo, Shiroyama, Takayuki, Koba, Taro, Torii, Yoshitaro, Sugimoto, Hiroyuki, Niki, Maiko, Mori, Masahide, Morimura, Osamu, Hirashima, Tomonori, Komuta, Kiyoshi, Kijima, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Japanese Society of Internal Medicine 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6548931/
https://www.ncbi.nlm.nih.gov/pubmed/30713297
http://dx.doi.org/10.2169/internalmedicine.1172-18

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6548931/
https://www.ncbi.nlm.nih.gov/pubmed/30713297
http://dx.doi.org/10.2169/internalmedicine.1172-18

Ejemplares similares